002773 康弘药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)8.67614.20913.8047.110-5.200
总资产报酬率 ROA (%)7.95412.85812.2196.034-4.207
投入资产回报率 ROIC (%)8.62614.05713.5166.877-4.430

边际利润分析
销售毛利率 (%)89.79788.92288.55090.16489.994
营业利润率 (%)35.76631.86629.9609.851-15.545
息税前利润/营业总收入 (%)34.22829.85729.0759.960-16.583
净利润/营业总收入 (%)29.92626.05525.54711.679-8.189

收益指标分析
经营活动净收益/利润总额(%)95.67593.23188.628111.772119.577
价值变动净收益/利润总额(%)2.2393.5823.6946.717-6.562
营业外收支净额/利润总额(%)-0.395-2.2001.4499.7211.391

偿债能力分析
流动比率 (X)8.6768.1076.0975.5424.044
速动比率 (X)8.0547.4905.6205.0993.799
资产负债率 (%)8.1088.41510.54112.23517.788
带息债务/全部投入资本 (%)-0.112-0.149-0.179-0.232--
股东权益/带息债务 (%)-88,485.216-66,839.353-55,068.346-41,848.930-17,254.009
股东权益/负债合计 (%)1,133.0811,087.270848.043715.530462.187
利息保障倍数 (X)-24.497-22.569-21.924-10.46020.254

营运能力分析
应收账款周转天数 (天)14.82014.10117.67625.6420.000
存货周转天数 (天)315.647301.598290.659271.7030.000